We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Oral Antidiabetic Agents in Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02091336
Recruitment Status : Unknown
Verified January 2014 by Hospital de Clinicas de Porto Alegre.
Recruitment status was:  Recruiting
First Posted : March 19, 2014
Last Update Posted : March 19, 2014
Information provided by (Responsible Party):
Hospital de Clinicas de Porto Alegre

Brief Summary:

The aim of this study is to determine the efficacy of oral treatment with glyburide and metformin controlling excessive fetal growth in women with gestational diabetes, using insulin as a ransom on no response to oral treatment .

It is randomized with women who seek care at the Outpatient Diabetes in Pregnancy in our hospital trial Eligible women between 18 - 45anos diagnosed with gestational diabetes , according to the WHO criteria , ratified the public network for prenatal care at the Clinic for Diabetes and Pregnancy HCPA .

Women with singleton pregnancy and gestational age not exceeding 30 weeks at the time of enrollment.

Pregnant women with indication for pharmacological treatment will be invited to randomization to use of oral , glyburide or metformin antidiabetic .

At regular intervals of 2 - 3 weeks fetal growth will be measured with obstetric ultrasonography , until birth.

The primary outcomes will be :

( 1 ) weight and gestational age at birth and the index of large for gestational age fetuses ( ≥ 90th percentile for gestational age ) ( 2 ) the use of insulin to achieve glycemic targets according to fetal growth , as an indirect measure of the inefficiency of oral medications .

Condition or disease Intervention/treatment Phase
Gestational Diabetes Drug: Metformin Drug: Glyburide Phase 4

Detailed Description:

The procedures for monitoring metabolic and obstetrical control , assessments of fetal well -being and indications for interruption are usually adopted in the Outpatient Diabetes and Pregnancy of the institution.

- Patients will be followed since their first appointment in our hospital, around the 20th week of pregnancy- until 8 weeks after labor and delivery. That being said, patients will be followed by an average of 28 weeks.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Oral Antidiabetic Agents on Gestational Diabetes: Modulating Effect on Fetal Growth - a Clinical Randomized Trial
Study Start Date : January 2014
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Glyburide
Glyburide 2,5 mg
Drug: Glyburide
patients treatment
Other Name: Glibenclamida, Glucovance
Active Comparator: Metformin
Metformin 500mg bid
Drug: Metformin
patients treatment
Other Name: Glucophage, Glifage

Primary Outcome Measures :
  1. fetal growth [ Time Frame: up to 9 months ]
    fetal growth will be assessed every 3 weeks by obstetric ultrasound during pregnancy until delivery

Secondary Outcome Measures :
  1. insulin requirements to achieve glucose targets [ Time Frame: up to 9 months ]
    every week patients will have one whole day in the hospital to monitor capillar glucose levels

Other Outcome Measures:
  1. hypoglycaemia [ Time Frame: up to 9 months ]
    medications will be suspended if patients present with repeated hypoglycaemia

  2. maternal weight gain [ Time Frame: up to 9 months ]
  3. neonatal 5th minute apgar [ Time Frame: 5 minutes after birth ]
  4. neonatal hypoglycaemia and respiratory distress [ Time Frame: 48 hours after birth ]
  5. neonatal need of intensive care [ Time Frame: 48 hours after birth ]
  6. need of c section [ Time Frame: day of birth ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Eligible women between 18-45 years diagnosed with gestational diabetes, according to the WHO criteria (19), ratified the public network for prenatal care at the Clinic for Diabetes and Pregnancy.
  • Women with singleton pregnancy and gestational age not exceeding 30 weeks at the time of enrollment, calculated from ultrasound (U.S.) Obstetric performed before the 20th week of pregnancy will be enrolled.

Exclusion Criteria:

  • Women who present enrollment in the diagnosis of chronic hypertension, heart disease or chronic lung disease intrauterine restricted or preterm labor, growth, or even chronic diarrhea will be excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02091336

Contact: Maria Lucia R Oppermann, PhD 55 51 33598117 maluopp@gmail.com
Contact: Vanessa K Genro, PhD 55 51 81313734 vanessagenro@gmail.com

Hospital de Clínicas de Porto Alegre Recruiting
Porto Alegre, RS, Brazil, 90035-903
Sponsors and Collaborators
Hospital de Clinicas de Porto Alegre
Study Chair: Maria Lucia R Oppermann, PhD Prf HCPA-UFRGS
Principal Investigator: Vanessa K Genro, PhD HCPA

Responsible Party: Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov Identifier: NCT02091336     History of Changes
Other Study ID Numbers: OAGM-001
First Posted: March 19, 2014    Key Record Dates
Last Update Posted: March 19, 2014
Last Verified: January 2014

Keywords provided by Hospital de Clinicas de Porto Alegre:
gestational diabetes
fetal growth
capillar glucose

Additional relevant MeSH terms:
Diabetes, Gestational
Pregnancy Complications
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs